Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma...

Patient-reported outcome (PRO) data were analyzed to explore the experience of chemotherapy-induced peripheral neuropathy (CIPN) symptoms by patients with newly-diagnosed advanced-stage classic Hodgkin lymphoma (AS-cHL) treated with BrECADD versus eBEACOPP, and explore the association of CIPN symptoms with health-related quality of life (HRQoL).

Participants' experience was assessed during treatment and follow-up periods in a phase 3 trial of AS-cHL patients treated with BrECADD or eBEACOPP by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - core 30-item (QLQ-C30) questionnaire and the 20-item Chemotherapy-Induced Peripheral Neuropathy module (QLQ-CIPN20). Item responses were examined at each visit to describe the experience of CIPN symptoms per treatment arm. The association between patient-reported sensory symptoms and HRQoL was explored by describing PRO scores between participants with and without sensory symptoms.

Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence followed a similar pattern over time across arms: they were reported during the treatment period, before gradually decreasing post-treatment. Motor symptoms were less reported than sensory symptoms. Participants with sensory symptoms showed poorer overall health and physical function, as well asmore fatigue than those without.

These exploratory PRO analyses highlight the occurrence of CIPN-related sensory symptoms, and to a lesser extent, motor symptoms, of AS-cHL patients treated with multiagent regimens. Treatments such as BrECADD may be associated with fewer CIPN sensory symptoms, which could prevent detrimental effects on patients' HRQoL.